Tenofovir alafenamide (TAF) keeps chronic hepatitis B virus (HBV) in check through 5 years of treatment, with an added benefit of improving bone and kidney safety outcomes in patients who have switched from tenofovir disoproxil fumarate (TDF), according to data from two ongoing phase III studies.
Patients with severe obesity who underwent sleeve gastrectomy (SG) had a significantly lower risk of fracture compared with those who underwent Roux-en-Y gastric bypass (RYGB) and those who did not undergo surgery, according to a recent study.
A faecal immunochemical test (FIT) is able to accurately rule out colorectal cancer (CRC) and is as sensitive as colonoscopy, the current gold standard for CRC diagnosis, the NICE* FIT study has shown.
An intravenous (IV) iron infusion before major open abdominal surgery does not reduce the risk of post-surgical mortality or need for blood transfusion in anaemic patients, according to the UK-based PREVENTT* trial.
Proton pump inhibitor has an irreplaceable role in the treatment of acid-related disorders, but prolonged use of the drug has been shown to bring a host of illnesses, and this time it is type 2 diabetes.
The addition of pertuzumab to standard perioperative chemotherapy (CT) comprising FLOT* and trastuzumab led to a significant improvement in pathologic complete response (pCR) in patients with HER2+ resectable oesophagogastric adenocarcinoma – at the expense however of higher toxicity rates, results of the phase II/III PETRARCA/FLOT 6 trial have shown.
In highly viraemic mothers, initiating treatment with tenofovir alafenamide fumarate (TAF) at the 13th gestational week or later in pregnancy puts a lid on hepatitis B virus (HBV) and prevents vertical transmission when infants receive standard immunoprophylaxis, as shown in a study.
Adding nivolumab to chemotherapy in the first-line setting significantly improves survival compared with chemotherapy alone in patients with HER2-negative advanced gastric/gastroesophageal (G/GEJ) cancer or oesophageal adenocarcinoma (EAC), shows the CheckMate 649 study presented at ESMO 2020.
In the treatment of patients with Crohn’s disease refractory to anti-tumour necrosis factor, ustekinumab is superior to vedolizumab in terms of steroid‐free remission and treatment persistence outcomes in both the induction and maintenance phases, as shown in the results of a comparative study.
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.